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Abstract
Purpose Surgery is the standard of care for resectable colo-
rectal liver metastases (CRC-LM). Unfortunately, 60 % of
patients develop secondary metastatic recurrence (SMR)
after R0-resection of CRC-LM. We investigated the impact
of surgical re-intervention and chemotherapy (Ctx) on sur-
vival in a consecutive series of patients with SMR.
Methods From 01/2001 to 11/2011, 104 out of 178 consecu-
tive patients with R0-resection of CRC-LM developed SMR
and were evaluated. The impact of surgical and Ctx re-
interventions on recurrence free (RFS) and cancer-specific
survival (CSS) was analyzed. Median follow-up was 28.0
(95 %CI: 19.4–37.4) months.
Results SMR occurred in 81 patients at a single site (49×
liver, 18× lung, 14× other) and in 23 patients at multiple
sites. Forty-two patients were scheduled for primary sur-
gery. Fifty-three patients were classified as non-resectable
and treated with median 5.0 [IQR, 3.0–10.0] cycles of Ctx,
combined with an EGFR/VEGF-antibody in 27 patients.
Nine patients received best supportive care only. R0/R1
resection could be achieved in 35 patients primarily and
even in 8 patients secondarily after Ctx. Surgical morbidity
and mortality were 16 and 0 %, respectively. The 5-year
RFS rates for patients with R0 versus R1-resection were 22
and 24 % (p=0.948). The 5-year CSS rate for R0/R1-
resected patients was 38 % versus 10 % for those patients
treated by Ctx alone (p<0.001).
Conclusion In SMR, surgical re-intervention is feasible and
safe in a remarkable number of patients and offers signifi-
cantly longer CSS compared to patients without resection.
Keywords Colorectal cancer . Liver resection . Second
metastatic recurrence . Conversion chemotherapy .
Secondary resectability
Introduction
Distant metastases are the predominant mode of failure of
adjuvant or neoadjuvant multimodal treatment in CRC.
More than 50 % of CRC patients experience distant metasta-
ses during the course of malignancy and the liver represents
the predominant site of first metastatic relapse (CRC-LM).
Regarding international guidelines, there is interdisciplinary
consensus that complete (R0) resection is the only curative
option in the treatment of patients with CRC-LM [1]. Five-
year overall survival (OS) rates up to 58% have been reported
by specialized centers [2], but primary liver resection is an
option only in 20 % of patients [3]. However, innovative
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treatment approaches like preoperative intensive intravenous
chemotherapy (Ctx) combined with targeted therapy (CELIM
trial [4]) and two-stage liver resection with portal vein ligation
[5, 6] have achieved secondary resectability in 28–75 % of
patients, initially deemed non-resectable. Recently, the
updated survival analysis of the CELIM trial has shown
a higher median OS of 46.7 months for R0-resected
patients compared to 27.3 months for non-resectable patients
(p=0.002). These data demonstrate that a Ctx-induced con-
version to secondary resectability is not only a technical issue
but also associated with a survival benefit [7].
Unfortunately, approximately 60 % of patients develop
early second metastatic recurrence (SMR) within 3 years
after the first liver resection [8]. The main sites of these
SMR are the liver or the lung but in 30 % of patients
multiple sites can be affected [9]. Previous studies have
demonstrated that in selected patients re-resection of isolated
hepatic [10–14] or pulmonal [15, 16] SMR might result not
only in encouraging survival rates similar to those after resec-
tion of the first metastatic recurrence but also in higher quality
of life compared to continued palliative Ctx [17]. In their
single-center experience, Adam et al. have even demonstrated
a 5-year OS of 34 % after the third hepatectomy for recurrent
liver metastases [18]. Therefore, efforts need to be focused on
optimizing multidisciplinary treatment regimens to increase
the number of patients suitable for resection of SMR. How-
ever, there is very rare evidence on the impact of surgery and
Ctx in a consecutive cohort of patients suffering from SMR
after previous R0-resection of first CRC-LM.
Therefore, in the present single-center study, we analyzed
the feasibility as well as impact of surgical re-intervention




From 01/2001 to 08/2011, 178 patients with liver-only
colorectal metastasis (CRM) underwent histopathologically
confirmed complete resection (R0-status was defined as
tumor free resection margin ≥0.1 cm) of all CRC-LM at
the Department of General and Visceral Surgery, Uni-
versity Medical Center Göttingen. Until the last date of
observation (November 30th 2011), 104 of these patients
developed SMR within a median recurrence free interval of
7.5 (95 %CI, 1.0–34.4) months. These patients represent
the actual study cohort. All patient data had been pro-
spectively collected in a database and study related procedures
were approved by the local ethics committee and in
accordance with the Helsinki Declaration of 1975, as
revised in 2008.
Table 1 summarizes the clinicopathological data of all
104 patients including treatment procedures of both, the
primary tumor and the first CRC-LM. Before resection of
CRC-LM the standardized staging covered clinical exami-
nation, serum level of carcinoembryonic antigen (CEA),
chest-X-ray or thoracic computed tomography (CT),
contrast-enhanced abdominal CT or magnetic resonance
imaging (MRI) and starting from 2006 on a fluorodeoxy-
glucose (18F)-positron emissions tomography (FDG-PET).
Standard treatment recommendation after first liver resec-
tion was a “wait and see”-strategy according to national S3-
guidelines [19]. Despite this fact, 35 patients were treated by
anti-CEA-radioimmunotherapy with 131I-labetuzumab
[20, 21] and 20 patients by Ctx according to the discretion
of the interdisciplinary tumor board or referring oncologist.
Prior to detection of SMR, 45 of 104 patients had received ≥2
systemic anticancer therapies (Ctx or radioimmunotherapy)
for either the primary tumor and/or the CRC-LM.
After diagnosis of SMR staging procedures were con-
cordant to those mentioned above. Given that there are
neither controlled trials nor established guidelines for the
treatment of SMR, interdisciplinary decision making in
individual patients considered extent of disease, perfor-
mance status, comorbidity, patients’ preference and inves-
tigators as well as institutional experience. Primary
resection of SMR was intended only in patients with lo-
calized single-site recurrences. When non-resectability or
unfavorable tumor biology, in particular rapid progression
was expected, Ctx was indicated with re-evaluation for
secondary resectability at regular intervals. Tumor re-
sponse to Ctx was measured using the Response Evalua-
tion Criteria In Solid Tumors criteria and classified as
complete response, partial response, stable disease or pro-
gressive disease [22]. Resection of SMR was performed
according to established surgical operating procedures.
Intraoperative ultrasound was used routinely in all patients
scheduled for repeated liver resection to detect occult he-
patic CRM. Cases with intraoperative open radiofrequency
ablation of single liver lesions in addition to surgery were
classified as incomplete (R1) resection. Median follow-up
interval from time of SMR diagnosis to last observation
was 28.0 (95 %CI, 19.4–37.4)months.
Statistical analysis
Statistical analysis was performed using the Statistical Com-
puting Software R (Free statistical software R, version
2.12.2, www.r-project.org). Recurrence free survival (RFS)
was calculated only for those patients who experienced R0/
R1-resection of SMR. Cancer-specific survival (CSS) was
calculated from the date SMR had been diagnosed on time
to cancer-specific death using the R package survival. Me-
dian survival data have to be interpreted as time to 50 % at
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risk. Survival data was visualized using Kaplan–Meier plots
and significance was calculated using the Cox Proportional
Hazards Model. Significance for comparison between
groups was calculated using Fisher’s Exact Test for categori-
cal variables or variables that were discretized (e.g., gender,
tumor stage, type of therapy) and using the Wilcoxon
Test for numeric variables (e.g., age, size of metastasis).
p values<0.05 were considered significant.
Results
Pattern of recurrence
The liver was the predominant site of second metastatic re-
currence (n=49). The second most common site was the lung
(n=18). Other localizations of single-site recurrences were
abdominal/retroperitoneal lymph nodes (n=4), locally in the
small pelvis (n=4), peritoneal (n=3), cerebral (n=2) and
osseous (n=1). Eleven patients developed simultaneous liver
and lung recurrences. Other coincidental localizations includ-
ed lung and brain (n=3), lung and abdominal/retroperitoneal
lymph nodes (n=2) and other double and triple combinations
in 7 additional patients. The pattern of SMR was not signifi-
cantly different between those patients who initially had uni-
lobar versus those who had bilobar CRC-LM (p=0.554).
Treatment of second metastatic recurrence
The treatment algorithm of SMR for the whole study cohort
is shown in Fig. 1. Forty-two of 104 patients were scheduled
for primary resection of SMR while 53 patients were deter-
mined as non-resectable and treated by palliative Ctx. Nine
Table 1 Clinicopathological data of primary tumor and first (liver-only)
metastatic recurrence
Parameter Patients (%) N=104
Agea 62.8 [56.5–67.6]
Gender
Female 43 (41 %)
Male 61 (59 %)
Primary tumor
Colon 55 (53 %)
Rectumb 49 (47 %)
Neoadjuvant radiochemotherapy
Yesc 16 (15 %)
No 82 (85 %)
Resection status
0 99 (95 %)
≥1 5 (5 %)
UICC stage
≤1 5 (5 %)
2 19 (18 %)
3 24 (23 %)
4 56 (54 %)
Adjuvant systemic chemotherapy 34 (33 %)
Number of liver metastasesa 2.0 [1.0–3.0]
Diameter of largest liver metastasis (cm)a 3.0 [2.0–5.0]
Preoperative systemic chemotherapy
5FU 8 (8 %)
5FU+oxaliplatin 29 (28 %)
5FU+irinotecan 8 (8 %)
+ cetuximab 5 (5 %)
+ bevacizumab 7 (7 %)
Number of cyclesa 4.0 [2.0–7.0]
More than one line 4 (9 %)
Type of resectiond
Minor 45 (43 %)
Major 59 (57 %)
2-stage with PVO 13 (13 %)
mT-stage [36]
1 10 (10 %)
2 37 (36 %)
3 17 (16 %)
4 40 (38 %)
Fong score[37]
0–2 64 (62 %)
3–5 40 (38 %)
Nordlinger score[38]
0–2 25 (24 %)
3–4 65 (63 %)
≥5 14 (13 %)
Postoperative (pseudo-adjuvant) therapy
5FU 3 (3 %)
5FU+oxaliplatin 11 (11 %)
Table 1 (continued)
Parameter Patients (%) N=104
5FU+irinotecan 6 (6 %)
+Cetuximab 2 (2 %)
+Bevacizumab 0 (0 %)
Radioimmunotherapy with 131I-labetuzumab 35 (34 %)
Number of cyclesa
Systemic chemotherapy 4.5 [3.0–8.0]
Radioimmunotherapy 1.0 [1.0–1.4]
UICC Union for International Cancer Control, 5FU 5-fluorouracil,
EGFR epidermal growth factor receptor, VEGF vascular endothelial
growth factor, PVO portal vein occlusion
a Expressed as median [IQR interquantile range]
b Up to 16 cm from the anal verve measured by rigid rectoscopy
c One patient with synchronous liver metastases received systemic
5FU-based chemotherapy only
dMinor resection is defined as <hemihepatectomy
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patients denied any further therapy or the performance status
was too poor for either surgery or Ctx. Therefore, these
patients received best supportive care only.
Detailed treatment data for all patients except those treated
by best supportive care are displayed in Table 2. In seven
patients scheduled for resection of SMR intraoperative find-
ings prevented macroscopically complete resection because of
occult disseminated peritoneal carcinomatosis (n=2), extend-
ed lymph node metastases (n=2), unresectable progressive
disease following portal vein ligation (n=1), inadequate rem-
nant liver volume after previous extended hemihepatectomy
and Ctx with oxaliplatin (n=1) and adjacence to vital cerebral
structures (n=1). All these seven patients received palliative
therapy. In detail, five patients were further treated by pallia-
tive Ctx, one patient with lymph node metastases requested
Ctx with hyperthermia, and one patient suffering from cere-
bral metastasis received cerebral radiotherapy alone.
Of those 53 patients treated by Ctx, 19 had multi-site
SMR and additional six patients had disseminated peritone-
al, lymphatic, or osseous disease. Patients who received Ctx
without either oxaliplatin or irinotecan were treated in the
early study period. As a result of Ctx, three patients had
complete radiographic remission of their metastases but
developed third metastatic disease during follow-up (wait
and watch strategy) localized at previous sites in all three
patients. Partial response or at least stable disease was
achieved in 16 patients. Of these 16 patients, 10 were
scheduled for surgical exploration. Four of the remaining
six patients had potentially resectable disease too, but three
patients refused surgical re-intervention and 1 patient pre-
ferred brachytherapy of his residual metastases. In all ten
patients scheduled for surgery, histopathologically con-
firmed R0-resection of targeted locoregional lesions could
be achieved. Nevertheless, two cases were classified as
incomplete (R2) resection because metastases at additional
sites were not resected. In detail, one patient with hepatic
and pulmonary SMR had divergent response to Ctx with
stable liver metastases but slightly progressive pulmonary
metastases. Based on good performance status and patients’
request all pulmonary lesions were resected by bilateral
thoracotomy. Postoperatively, the patient received Ctx and
was alive as of the last observation. A second patient had
pulmonary and cerebral metastases and experienced resec-
tion of cerebral metastases only as the lung metastases
remained in stable disease status. However, this patient
suffered from cerebral recurrence and died 22 months after
surgery. The residuary 33 patients, classified as non-resectable
for SMR, had progressive disease under continued Ctx and
received up to five lines of palliative Ctx.
To identify differences in CRC biology and disease stage
between the subgroups (primary resection, secondary resec-
tion, Ctx only) we performed pairwise comparisons for
SMR-related parameters, in particular RFS (from previous
liver resection to diagnosis of SMR) and number as well as
largest diameter of SMR (Table 3). RFS and number of
lesions were not statistically different distributed between
the subgroups. The diameter of metastases was significantly
greater in patients treated by Ctx only compared to those
with primary resection of SMR (p=0.0465). Furthermore,
metastatic affection of multiple sites was more often in
patients treated by Ctx only compared to patients with
primary or secondary resection (p<0.001).
Survival
RFS rates were calculated for patients with R0- and R1-
status after resection of SMR. The 5-year RFS rates between
R0 and R1 status were nearly identical with 22 versus 24 %,
Fig. 1 Therapy algorithm for
second metastatic recurrence.
Primary and secondary R0/R1-
resection could be achieved in
35 and 8 patients, respectively.






hyperthermia (n=1) while one
patient denied further therapy.
CRC colorectal cancer
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respectively (p=0.948, Fig. 2a). During follow-up, one patient
with non-resectable intrahepatic relapse and three patients
without evidence of recurrent disease died non-cancer related.
For comparison of CSS rates between different oncological
treatment procedures, all patients receiving best supportive
care were excluded. Patients receiving potentially curative
resection (R0/R1) of SMR had a 5-year survival rate
of 38 % versus 10 % for patients with non-resectable
malignancy continuously treated by palliative Ctx alone
(p<0.001, Fig. 2b).
Discussion
During the last 10 years, treatment options in patients with
metastatic colorectal cancer have been evolved by initiation
of multidisciplinary therapeutic strategies. Most of these are
using modern chemotherapeutic regimens including agents
for targeted therapy as well as extended surgery to remove
(residual) metastases. Thereby, the number of primarily or
secondarily resected patients is increasing. Given that
approximately two thirds of these patients experience
relapse again, surgeons as well as medical oncologists









Agea 62.9 [57–68.5] 65.3 [57.6–69.2]
Gender
Female 16 (38 %) 22 (42 %)
Male 26 (62 %) 31 (58 %)
Side of recurrence
Liver 31 (74 %) 14 (26 %)
Lung 5 (12 %) 13 (25 %)
Portal or retroperitoneal
lymph nodes
1 (2 %) 3 (6 %)
Pelvic mass/local recurrence 3 (7 %) 1 (2 %)
Peritoneal carcinomatosis 1 (2 %) 2 (4 %)
Cerebral 1 (2 %) –
Osseous – 1 (2 %)
Lung + Liver – 11 (21 %)
Lung + other – 6 (11 %)
Other multiple sides – 2 (4 %)
Number of metastases
pretherapeutica
1 [1.0–2.0] 4 [2.0–6.0]
Diameter of largest metastasis
pretherapeutic (cm)a
1.9 [1.0–2.5] 2.5 [1.5–3.5]
Systemic 5FU-based chemotherapy (first-line)
5FU – 5 (9 %)
5FU+oxaliplatin – 19 (36 %)
5FU+irinotecan – 29 (55 %)
additional cetuximab – 10 (19 %)
additional bevacizumab – 18 (34 %)
Number of cyclesa – 5.0 [3.0–10.0]
Effect of systemic 5FU-based chemotherapy
Progressive disease – 34 (64 %)
Stable disease – 11 (21 %)
Partial response – 5 (9 %)
Complete response – 3 (6 %)
Surgical Procedure
Surgical exploration only 3 (7 %) –
Surgical exploration + RFA liver 4 (10 %) –
Non-anatomic liver resection 18 (43 %) 2 (20 %)
Bisegmentectomy 2 (5 %) –
Bisegmentectomy + non-
anatomic liver resection
– 1 (10 %)
Hemihepatectomy 3 (7 %) –
Trisectorectomy 1 (2 %) –
Rectal resection 3 (7 %) –
Rectal extirpation + non-
anatomic liver resection
– 1 (10 %)
Rectal extirpation + pulmonary
wedge resection
– 1 (10 %)
Pulmonary wedge resection 5 (12 %) 3 (30 %)











R0 26 (62 %) 8 (80 %)
R1 9 (21 %) 0 (0 %)
R2 7 (17 %) 2 (20 %)
Surgical morbidity 16 % 13 %
Surgical mortality 0 % 0 %
Postoperative treatment (only R0/R1-resections)
None 16 (46 %) 4 (46 %)
Systemic 5FU-based
chemotherapy
8 (23 %) 3 (38 %)
5FU alone 0 (0 %) 1 (13 %)
5FU + oxaliplatin 3 (9 %) 0 (0 %)
5FU + irinotecan 5 (14 %) 2 (25 %)
additional EGFR/
VEGF-antibody
2 (6 %) 1 (13 %)
Number of cyclesa 4.5 [2.8–6.5] 4.0 [2.5–4.5]
Radioimmunotherapy with
131I-labetuzumab
9 (26 %) 1 (13 %)
Number of cyclesa 1.0 [1.0–2.0] 2.0 [2.0–2.0]
Radiotherapy 2 (6 %) 2 (25 %)
RFA radiofrequency ablation, 5FU 5-fluorouracil, EGFR epidermal
growth factor receptor, VEGF vascular endothelial growth factor
a Expressed as median [IQR
interquantile range]
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are faced in clinical practice with a growing number of
patients with SMR requesting further treatment. There-
fore, data on what can be achieved in these patients by
surgery and/or Ctx are needed.
Our single-center series of consecutive patients after R0-
resection of CRC-LM has shown that repeated resection of
SMR is feasible and safe in 40 % of patients. After re-
resection of SMR patients showed a significantly longer
CSS compared to non-resected patients treated by palliative
Ctx alone.
Pattern of recurrence and previous oncological treatment
The pattern of SMR observed in our series was comparable
to previous reports [8, 9, 23]. Stratifying patients according
to the hepatic spread (unilobar versus bilobar) of initial
CRC-LM, we could not observe the expected higher rate
of intrahepatic SMR in the bilobar cohort. Repeated liver
resection needed to be canceled only in one patient due to
small remnant liver volume as reported. In contrast, in
10 of 28 patients with intrahepatic SMR scheduled for
re-resection extended hemihepatectomies had been per-
formed for initial CRC-LM. The postoperative course in
all 28 patients was uneventful. In consequence, extended
previous liver resections do not necessarily prohibit repeated
resections for SMR as long as individual limitations, in par-
ticular liver tissue damage and involvement of vital anatomic
structures are absent.
Treatment of second metastatic recurrence
There is very limited evidence on what can be recommended
in patients with SMR. However, the goal of therapeutic inter-
vention should be prolonged OS with acceptable quality of
life and, if possible, without ongoing cytotoxic therapy. Ger-
man guidelines [24] on the treatment of metastatic colorectal
cancer do not include algorithms for patients with SMR after
R0-resection of CRC-LM In contrast, the National Compre-
hensive Cancer Network guidelinesmention that SMR limited
to either liver or lung can be considered for re-resection in
selected patients [25]. The crucial aspect of reasonable
weighting treatment decisions is how to interpret the
Table 3 Distribution of second
metastatic recurrence related
parameters between patients
treated by primary surgery,
secondary surgery and
chemotherapy only
aExpressed as median [IQR
interquantile range]







Number of metastasesa 1.0 [1.0–2.0] 3.0 [2.0–6.5] 4.0 [2.0–6.0]
Diameter of largest metastasis (cm)a 1.9 [1.0–2.5] 2.5 [2.0–2.6] 2.0 [1.5–3.5]
Recurrence free survival in monthb 7.9 [ 0.6–29.6] 9.4 [1.4–23.0] 6.8 [1.6–34.5]
Unilobar and bilobar liver metastases as
first metastatic recurrence
20/15 4/4 28/24
Fig. 2 Kaplan–Meier curve for recurrence free and cancer-specific
overall survival. a Recurrence free survival for patients with R0 versus
R1 resection of second metastatic recurrence (n=43). Five-year RFS
rates for R0- and R1-resected patients were 22 and 24 % (p=0.948). b
Overall cancer-specific survival for patients with R0/R1 resection
versus R2-resection+palliative chemotherapy/palliative chemotherapy
only for second metastatic disease (n=95). Five-year CSS rate was
38 % for R0/R1-resected patients versus 10 % for patients treated by
palliative chemotherapy (p<0.001)
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occurrence of SMR. Premature data from the SECA-trial
evaluating the impact of liver transplantation in selected
patients with unresectable CRC-LM showed that different
from patients after resection of CRC-LM the majority of
patients treated by liver transplantation developed extrahepat-
ic recurrence [26]. These data support the hypothesis that to a
certain extent occurrence of SMR more likely represents
outgrowth of previously occult micrometastases instead
of increasing aggressiveness. Therefore, when resection is
the standard in initial CRC-LM, it would be consequent to aim
for resection in SMR as well. Given that only 20 % of initial
CRC-LM are considered resectable [3], our primary resection
rate of 34 % in patients with SMR is encouraging. Resection
rate and low morbidity, which has also been reported by
Brachet et al. [27], further support multimodal treatment
concepts including repeated surgery in patients suffering
from SMR.
In the setting of initially unresectable CRC-LMCtx-related
conversion rates of 38–60 % to secondary resectability have
been observed by using monoclonal EGFR/VEGF-antibodies
in addition to Ctx [4, 28, 29]. In our study, secondary resection
of SMR was performed in 15 % of patients initially
treated with Ctx. Considering that four additional patients had
resectable disease after Ctx, the percentage of resectable
patients in this cohort even raised up to 23 %. However,
monoclonal EGFR/VEGF-antibodies were introduced into
clinical routine not until the second half period of the present
study. We hypothesize that an even larger proportion of
patients would qualify for secondary resection by using
intensified Ctx protocols as investigated for example in the
CELIM trial [8].
Although van der Pool et al. [30] found no difference in
survival between patients with recurrent hepatic CRM trea-
ted by either RFA or liver resection, we classified patients
sufficiently treated by RFA as R1 (n=5). A further four
patients classified with R1-status had liver resections with
the tumor being adjacent to remnant liver veins (n=2),
resection of local recurrence limited by the sacrum (n=1)
and resection of local peritoneal carcinomatosis (n=1). In all
these patients, macroscopically complete resection was
achieved. De Haas et al. [31] reported that survival following
R1-liver resection is comparable to R0-resection. RFS in our
nine patients classified as R1 was not significantly different
compared to R0-resected patients. Therefore, we grouped
patients with R0 and R1-resection together for CSS analysis
and observed a significantly longer CSS compared to patients
treated by palliative Ctx only. In concordance with Mise et al.
[32] who evaluated resection in selected patients with single
and multiple sites SMR, we consider a survival benefit when
resection of SMR can be achieved.
Very recently, Hill et al. [33] proposed a scoring system
to predict survival in patients with SMR based on three
different parameters: CEA>200 ng/ml, >1 liver metastases
and >5 cm liver metastases. Such scoring system would be
very useful to stratify patients into different treatment concepts
in particular primary resection versus preoperative chemother-
apy. As we observed significant influence of treatment on
survival, we advocate validating this initial experience in a
larger independent patient cohort including treatment data.
It should be noted that the data of this retrospective study
on patients in this advanced stage of disease with SMR are
biased. Patients were not prospectively randomized into
different treatment arms. The indication for the chemother-
apy regimens was based on tumor biology (progression),
toxicity and efficacy of previously applied therapies, intro-
duction of innovative agents into clinical routine and physi-
cians’ discretion (multidisciplinary tumor board decision).
However, in contrast to previous reports focusing on highly
selected patients we present a consecutive series of patients
with SMR. All patients have been treated in our center after
introduction of advanced surgical techniques. The treatment
decisions were consistently made by the same multidisci-
plinary team. Thereby, patients with resectable and non-
resectable SMR were included and randomization could
not be realized. Addressing disease aggressiveness, multiple
site recurrences were significantly more frequent in the Ctx
only group. However, although first-line trials suggest that
multiple site recurrences have poorer survival compared to
single-site recurrences [34] these data have not been
confirmed in a well described patient cohort with SMR
treated in a multimodality concept including resection.
Pairwise comparisons between the study groups (Table 3)
showed that parameters expressing more aggressive disease
were mainly balanced. Therefore, selection bias considering
patients with more favorable tumor biology or lower tumor
load for primary resection seems to be unlikely. Recently, the
meta-analysis of Gonzales et al. did not find a significant
impairment of survival by previous liver resection for concom-
itant liver metastases compared to lung only metastases [35].
Conclusion
Surgical re-intervention is a feasible and safe treatment
option in a remarkable number of patients with SMR follow-
ing R0-resection of CRC-LM. Secondary resection after Ctx is
possible in a remarkable proportion of patients initially
deemed to be non-resectable. In our single-center series,
patients who were treated within a multidisciplinary concept
including R0/R1-resection of SMR had a significantly longer
CSS compared to those who were treated by Ctx only. There-
fore, all patients with SMR after R0-resection of CRC-LM
should be discussed in a multidisciplinary team prior to any
treatment onset. The possibility of repeated surgical interven-
tion needs to be assessed by a surgeon experienced in onco-
logical strategies as well as liver surgery.
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